AptarGroup (ATR) Inks Deal to Create Digital Health Solutions

Group 1 - AptarGroup, Inc.'s Aptar Digital Health has signed an enterprise agreement with Biogen Inc. to develop digital health solutions for neurological and rare diseases [1] - The collaboration will enhance AptarGroup's position as a partner for the pharmaceutical industry, providing a comprehensive portfolio of device solutions, services, and technology [1] - Biogen will transfer ownership of certain digital health solutions to Aptar Digital Health, which will include product management, software design, secure cloud hosting, and marketing support [1] Group 2 - Biogen has developed flagship digital health products that have benefited patients in over 15 countries, and the collaboration will significantly expand Aptar Digital Health's activities in neurology and immunology [2] - The initial solutions for North America, Europe/the U.K., Asia Pacific, and Latin America include Cleo/Aby and Physio.me, with plans to develop solutions for spinal muscular atrophy, Friedreich's ataxia, and lupus [2] - AptarGroup reported fourth-quarter 2023 adjusted earnings per share of $1.21, exceeding the Zacks Consensus Estimate of $1.12, marking a 27% increase from the previous year's 95 cents per share [2] Group 3 - Total revenues for AptarGroup increased by 5.3% year over year to $838 million, surpassing the Zacks Consensus Estimate of $832 million [3] - The company's shares have gained 28.3% over the past year, significantly outperforming the industry's 0.2% rise [4]